Compass Therapeutics (CMPX) Earnings Date, Estimates & Call Transcripts $1.62 -0.04 (-2.11%) (As of 12:44 PM ET) Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Compass Therapeutics Latest Earnings SummaryUpcoming Earnings DateMar. 20EstimatedActual EPS (Nov. 12) -$0.08 Beat By $0.03 Consensus EPS (Nov. 12) -$0.11 Compass Therapeutics released Q3 2024 earnings on November 12, 2024, reporting an EPS of -$0.08, which beat the consensus estimate of -$0.11 by $0.03. With a trailing EPS of -$0.37, Compass Therapeutics' earnings are expected to decrease next year, from ($0.35) to ($0.43) per share. CMPX Upcoming EarningsCompass Therapeutics' next earnings date is estimated for Thursday, March 20, 2025, based off prior year's reporting schedules. Get Compass Therapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Compass Therapeutics and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataCMPX Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.CMPX Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Porter & CompanyElection warning coming true… If you missed it, my emergency election broadcast is now available - watch it before it's too late.Click here to watch it now. Compass Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20242-$0.14-$0.11-$0.13Q2 20243-$0.11-$0.09-$0.10Q3 20243-$0.14-$0.11-$0.12Q4 20243-$0.17-$0.07-$0.12FY 202411-$0.56-$0.38-$0.46Q1 20251-$0.07-$0.07-$0.07Q2 20251-$0.08-$0.08-$0.08Q3 20251-$0.07-$0.07-$0.07Q4 20251-$0.07-$0.07-$0.07FY 20254($0.29)($0.29)($0.29) Compass Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails 3/20/2025(Estimated)-------11/12/2024--$0.11-$0.08+$0.03-$0.08--8/12/2024--$0.10-$0.10--$0.10-$0.85M5/13/2024Q1 2024-$0.11-$0.08+$0.03-$0.08--3/21/2024Q4 2023-$0.09-$0.11 -$0.02-$0.11--11/9/2023Q3 2023-$0.11-$0.08+$0.03-$0.08--8/3/2023Q2 2023-$0.08-$0.09 -$0.01-$0.09-- Get the Latest News and Ratings for CMPX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Compass Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 5/4/2023Q1 2023-$0.11-$0.06+$0.05-$0.06--3/15/2023Q4 2022-$0.11-$0.10+$0.01-$0.10-- Compass Therapeutics Earnings - Frequently Asked Questions When is Compass Therapeutics's earnings date? Compass Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, March 20th, 2025 based off last year's report dates. Learn more on CMPX's earnings history. Did Compass Therapeutics beat their earnings estimates last quarter? In the previous quarter, Compass Therapeutics (NASDAQ:CMPX) reported ($0.08) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.11) by $0.03. Learn more on analysts' earnings estimate vs. CMPX's actual earnings. How much profit does Compass Therapeutics generate each year? Compass Therapeutics (NASDAQ:CMPX) has a recorded net income of -$42.49 million. CMPX has generated -$0.37 earnings per share over the last four quarters. What is Compass Therapeutics's EPS forecast for next year? Compass Therapeutics's earnings are expected to decrease from ($0.35) per share to ($0.43) per share in the next year. More Earnings Resources from MarketBeat Related Companies Poseida Therapeutics Earnings Date Erasca Earnings Date Autolus Therapeutics Earnings Date Immunome Earnings Date Kura Oncology Earnings Date Evolus Earnings Date Rapport Therapeutics Earnings Date Prothena Earnings Date Tyra Biosciences Earnings Date CARGO Therapeutics Earnings Date Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Alibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of EarningsLam Research Proves Analysts Wrong with a Strong Earnings Report Election warning coming true… (Ad)If you missed it, my emergency election broadcast is now available - watch it before it's too late.Click here to watch it now. This page (NASDAQ:CMPX) was last updated on 12/3/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredIs NVDA a sell? Buy this stock instead before Dec 3After months of speculation that Nvidia was "cooling off..." and "running out of steam..." The company is m...Chaikin Analytics | SponsoredEven Trump can’t stop what’s coming.No matter who sits in the White House over the next four years, a series of events has been triggered that cou...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Compass Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Compass Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
